Sabra Healthcare REIT Inc's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Sabra Healthcare REIT Inc reported revenue of $774.6M (+10.2% year on year) and net income of $155.6M (+22.8% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Rental and related revenues | $374.1M | $381.5M | $376.3M | $400.6M |
| Resident fees and services | $356.9M | $284.6M | $236.2M | $186.7M |
| Interest and other income | $43.6M | $37.2M | $35.1M | $37.6M |
| Total revenues | $774.6M | $703.2M | $647.5M | $624.8M |
| Depreciation and amortization | $187.0M | $169.6M | $183.1M | $187.8M |
| Interest | $112.5M | $115.3M | $113.0M | $105.5M |
| Operating expenses | $271.1M | $227.1M | $195.2M | $162.6M |
| General and administrative | $53.7M | $50.1M | $47.5M | $39.6M |
| (Recovery of) provision for loan losses | ($1.0M) | ($571.0K) | $191.0K | $141.0K |
| Impairment of real estate | $7.3M | $18.5M | $14.3M | $94.0M |
| Total expenses | $630.6M | $580.0M | $553.3M | $589.6M |
| Loss on extinguishment of debt | ($1.2M) | $0 | ($1.5M) | ($411.0K) |
| Other income | $14.0M | $2.7M | $2.6M | ($1.1M) |
| Net (loss) gain on sales of real estate | ($3.5M) | $2.1M | ($76.6M) | ($12.0M) |
| Total other income (expense) | $9.4M | $4.8M | ($75.6M) | ($13.5M) |
| Income before income (loss) from unconsolidated joint ventures and income tax expense | $153.4M | $128.1M | $18.7M | $21.7M |
| Income (loss) from unconsolidated joint ventures | $3.9M | ($397.0K) | ($2.9M) | ($98.0M) |
| Income tax expense | ($1.8M) | ($1.0M) | ($2.0M) | ($1.2M) |
| Net income | $155.5M | — | — | — |
| Net loss attributable to noncontrolling interests | $99.0K | — | — | — |
| Net income attributable to Sabra Health Care REIT, Inc. | $155.6M | $126.7M | $13.8M | ($77.6M) |
| Basic common share (in dollars per share) | $0.64 | $0.54 | $0.06 | -$0.34 |
| Diluted common share (in dollars per share) | $0.64 | $0.54 | $0.06 | -$0.34 |
| Weighted-average number of common shares outstanding, basic (in shares) | 241.3M | 233.5M | 231.2M | 230.9M |
| Weighted-average number of common shares outstanding, diluted (in shares) | 244.5M | 236.0M | 232.8M | 230.9M |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Rental and related revenues (Note 6) | $101.3M | $95.0M | $85.4M | $99.8M |
| Resident fees and services | $128.8M | $116.7M | $92.0M | $79.0M |
| Interest and other income | $5.8M | $10.0M | $12.7M | $10.3M |
| Total revenues | $235.9M | $221.8M | $190.0M | $189.2M |
| Depreciation and amortization | $56.4M | $53.1M | $48.5M | $43.6M |
| Interest | $29.8M | $28.4M | $28.9M | $27.5M |
| Operating expenses | $92.3M | $85.6M | $69.7M | $61.1M |
| General and administrative | $16.8M | $14.9M | $12.6M | $12.5M |
| Provision for (recovery of) loan losses and other reserves | $102.4M | ($213.0K) | ($240.0K) | ($227.0K) |
| Impairment of real estate | $0 | $440.0K | $2.6M | $4.1M |
| Total expenses | $297.7M | $182.3M | $162.0M | $148.6M |
| Other (expense) income | ($2.7M) | ($55.0K) | ($769.0K) | $14.7M |
| Net gain on sales of real estate | $37.7M | — | ($4.4M) | $10.0M |
| Total other income | $35.0M | — | ($6.4M) | $24.7M |
| (Loss) income before income from unconsolidated joint ventures and income tax expense | ($26.8M) | $39.4M | $21.7M | $65.2M |
| Income from unconsolidated joint ventures | $2.2M | $1.9M | $1.2M | $832.0K |
| Income tax expense | ($678.0K) | ($526.0K) | ($436.0K) | ($497.0K) |
| Net (loss) income | ($25.2M) | $40.8M | $22.5M | — |
| Net loss attributable to noncontrolling interests | $46.0K | $67.0K | $21.0K | — |
| Net (loss) income attributable to Sabra Health Care REIT, Inc. | ($25.2M) | $40.9M | $22.5M | $65.5M |
| Basic common share (in dollars per share) | -$0.10 | $0.16 | $0.09 | $0.28 |
| Diluted common share (in dollars per share) | -$0.10 | $0.16 | $0.09 | $0.27 |
| Weighted average number of common shares outstanding, basic (in shares) | 252.3M | 252.1M | 239.9M | 238.0M |
| Weighted average number of common shares outstanding, diluted (in shares) | 252.3M | 256.0M | 243.6M | 240.9M |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Real estate investments, net of accumulated depreciation of $1,224,663 and $1,102,030 as of December 31, 2025 and 2024, respectively | $4.7B | $4.5B | $4.6B | $5.0B |
| Loans receivable and other investments, net | $434.1M | $442.6M | $420.6M | $411.4M |
| Investment in unconsolidated joint ventures | $118.2M | $121.8M | $136.8M | $135.0M |
| Cash and cash equivalents | $71.5M | $60.5M | $41.3M | $49.3M |
| Restricted cash | $6.6M | $5.9M | $5.4M | $4.6M |
| Lease intangible assets, net | $65.3M | $27.5M | $30.9M | $40.1M |
| Accounts receivable, prepaid expenses and other assets, net | $111.3M | $131.8M | $133.8M | $147.9M |
| Total assets | $5.5B | $5.3B | $5.4B | $5.7B |
| Secured debt, net | $43.3M | $45.3M | $47.3M | $49.2M |
| Revolving credit facility | $217.6M | $106.6M | $94.4M | $197.0M |
| Term loans, net | $1.0B | $529.8M | $537.1M | $526.1M |
| Senior unsecured notes, net | $1.2B | $1.7B | $1.7B | $1.7B |
| Accounts payable and accrued liabilities | $119.3M | $117.9M | $137.0M | $142.3M |
| Lease intangible liabilities, net | $21.4M | $26.8M | $32.5M | $42.2M |
| Total liabilities | $2.7B | $2.6B | $2.6B | $2.7B |
| Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 |
| Common stock, $0.01 par value; 500,000,000 shares authorized, 251,697,456 and 237,586,882 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2.5M | 2.4M | 2.3M | 2.3M |
| Additional paid-in capital | $4.8B | $4.6B | $4.5B | $4.5B |
| Cumulative distributions in excess of net income | ($2.0B) | ($1.9B) | ($1.7B) | ($1.5B) |
| Accumulated other comprehensive (loss) income | ($3.6M) | $20.9M | $23.7M | $19.1M |
| Total Sabra Health Care REIT, Inc. stockholders’ equity | $2.8B | $2.7B | $2.8B | $3.1B |
| Noncontrolling interests | $1.9M | — | — | — |
| Total equity | $2.8B | — | — | — |
| Total liabilities and equity | $5.5B | $5.3B | $5.4B | $5.7B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Real estate investments, net of accumulated depreciation of $1,297,557 and $1,224,663 as of June 30, 2026 and December 31, 2025, respectively | $4.8B | $4.7B | $4.6B | $4.5B |
| Loans receivable and other investments, net | $115.1M | $432.9M | $436.5M | $441.0M |
| Investment in unconsolidated joint ventures | $113.9M | $116.5M | $117.9M | $126.4M |
| Cash and cash equivalents | $231.6M | $116.5M | $200.6M | $95.2M |
| Restricted cash | $6.8M | $6.9M | $6.9M | $6.5M |
| Lease intangible assets, net | $83.0M | $67.4M | $59.8M | $24.7M |
| Accounts receivable, prepaid expenses and other assets, net | $130.1M | $148.1M | $113.2M | $155.0M |
| Total assets | $5.5B | $5.6B | $5.6B | $5.3B |
| Secured debt, net | $42.2M | $42.8M | $43.8M | $44.3M |
| Revolving credit facility | $317.5M | $355.0M | $282.2M | $163.0M |
| Term loans, net | $1.0B | $1.0B | $1.0B | $535.9M |
| Senior unsecured notes, net | $1.2B | $1.2B | $1.2B | $1.7B |
| Accounts payable and accrued liabilities | $115.0M | $117.9M | $124.0M | $113.1M |
| Lease intangible liabilities, net | $19.1M | $20.2M | $22.6M | $23.8M |
| Total liabilities | $2.8B | $2.8B | $2.7B | $2.6B |
| Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 |
| Common stock, $0.01 par value; 500,000,000 shares authorized, 255,462,756 and 251,697,456 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 2.6M | 2.5M | 2.5M | 2.4M |
| Additional paid-in capital | $4.9B | $4.8B | $4.8B | $4.6B |
| Cumulative distributions in excess of net income | ($2.2B) | ($2.0B) | ($2.0B) | ($1.9B) |
| Accumulated other comprehensive income (loss) | $6.1M | $691.0K | ($6.0M) | ($2.0M) |
| Total Sabra Health Care REIT, Inc. stockholders’ equity | $2.8B | $2.8B | $2.8B | $2.7B |
| Noncontrolling interests | $1.7M | $1.9M | $2.0M | — |
| Total equity | $2.8B | $2.8B | $2.8B | — |
| Total liabilities and equity | $5.5B | $5.6B | $5.6B | $5.3B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income | $155.5M | — | — | — |
| Depreciation and amortization | $187.0M | $169.6M | $183.1M | $187.8M |
| Non-cash rental and related revenues | ($1.0M) | ($3.9M) | ($8.7M) | $2.2M |
| Non-cash interest income | $7.0K | $29.0K | ($372.0K) | ($2.3M) |
| Non-cash interest expense | $8.0M | $10.5M | $12.3M | $11.1M |
| Stock-based compensation expense | $11.4M | $9.0M | $7.9M | $7.5M |
| Loss on extinguishment of debt | $1.2M | $0 | $1.5M | $411.0K |
| (Recovery of) provision for loan losses | ($1.0M) | ($571.0K) | $191.0K | $141.0K |
| Net loss (gain) on sales of real estate | $3.5M | ($2.1M) | $76.6M | $12.0M |
| Impairment of real estate | $7.3M | $18.5M | $14.3M | $94.0M |
| (Income) loss from unconsolidated joint ventures | ($3.9M) | $397.0K | $2.9M | $40.3M |
| Distributions of earnings from unconsolidated joint ventures | $7.8M | $5.4M | $3.5M | $0 |
| Other non-cash items | ($17.2M) | ($534.0K) | ($3.7M) | $2.2M |
| Accounts receivable, prepaid expenses and other assets, net | ($11.4M) | ($15.5M) | ($11.1M) | ($6.4M) |
| Accounts payable and accrued liabilities | $1.6M | ($7.1M) | $8.3M | ($13.3M) |
| Net cash provided by operating activities | $348.6M | $310.5M | $300.6M | $315.7M |
| Acquisition of real estate and lease intangibles | ($452.9M) | ($136.4M) | ($78.5M) | ($92.2M) |
| Origination and fundings of loans receivable | ($6.9M) | ($21.6M) | ($11.4M) | ($23.8M) |
| Origination and fundings of preferred equity investments | ($9.0K) | ($2.8M) | ($11.0M) | ($8.0M) |
| Additions to real estate | ($41.5M) | ($54.7M) | ($84.9M) | ($54.5M) |
| Repayments of loans receivable | $20.7M | $3.6M | $9.3M | $5.3M |
| Repayments of preferred equity investments | $2.5M | $5.9M | $5.5M | $5.4M |
| Investment in unconsolidated joint ventures | ($1.2M) | ($1.3M) | ($5.2M) | ($142.9M) |
| Net proceeds from the sales of real estate | $88.6M | $96.0M | $247.6M | $87.3M |
| Net proceeds from sales-type lease | $0 | $0 | $25.5M | — |
| Proceeds from net investment hedges | $4.5M | — | — | — |
| Insurance proceeds | $1.6M | $2.4M | $5.8M | — |
| Distributions in excess of earnings from unconsolidated joint ventures | $6.8M | $0 | $544.0K | $0 |
| Net cash (used in) provided by investing activities | ($378.0M) | ($109.0M) | $103.1M | ($216.2M) |
| Net borrowings from revolving credit facility | $109.8M | $14.6M | ($104.3M) | $204.0M |
| Principal payments on senior unsecured notes | ($500.0M) | — | $0 | $0 |
| Proceeds from term loans | $500.0M | $0 | $12.2M | — |
| Principal payments on secured debt | ($2.1M) | ($2.0M) | ($2.0M) | ($17.5M) |
| Payments of deferred financing costs | ($4.4M) | ($94.0K) | ($18.1M) | ($20.0K) |
| Payments related to extinguishment of debt | ($2.9M) | — | $0 | $0 |
| Contributions from noncontrolling interests | $2.0M | — | — | — |
| Payment of contingent consideration | $0 | $0 | ($17.9M) | ($2.5M) |
| Issuance of common stock, net | $227.8M | $86.1M | ($2.7M) | ($4.8M) |
| Dividends paid on common stock | ($289.5M) | ($280.1M) | ($277.4M) | ($277.2M) |
| Net cash provided by (used in) financing activities | $40.8M | ($181.6M) | ($410.3M) | ($161.7M) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $11.4M | $20.0M | ($6.6M) | ($62.2M) |
| Effect of foreign currency translation on cash, cash equivalents and restricted cash | $391.0K | ($359.0K) | ($614.0K) | $268.0K |
| Cash, cash equivalents and restricted cash, beginning of period | $66.3M | $46.7M | $53.9M | $115.9M |
| Cash, cash equivalents and restricted cash, end of period | $78.1M | $66.3M | $46.7M | $53.9M |
| Interest paid | $111.0M | $105.2M | $102.4M | $97.7M |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income | $15.6M | $40.8M | $128.4M | $105.8M |
| Depreciation and amortization | $109.5M | $53.1M | $135.6M | $87.1M |
| Non-cash rental and related revenues | ($5.3M) | ($1.6M) | $820.0K | ($6.3M) |
| Non-cash interest income | $1.0K | $0 | $7.0K | $7.0K |
| Non-cash interest expense | $4.7M | $2.4M | $5.6M | $3.5M |
| Stock-based compensation expense | $7.2M | $3.1M | $8.3M | $5.4M |
| Provision for (recovery of) loan losses and other reserves | $102.2M | ($213.0K) | ($640.0K) | ($400.0K) |
| Net gain on sales of real estate | ($37.7M) | — | ($5.5M) | ($10.0M) |
| Impairment of real estate | $440.0K | $440.0K | $6.7M | $4.1M |
| Income from unconsolidated joint ventures | ($4.1M) | ($1.9M) | ($2.3M) | ($1.1M) |
| Distributions of earnings from unconsolidated joint ventures | $4.2M | $1.7M | $5.9M | $4.0M |
| Other non-cash items | $0 | — | ($17.2M) | ($17.2M) |
| Accounts receivable, prepaid expenses and other assets, net | ($11.9M) | ($1.5M) | ($9.1M) | ($6.9M) |
| Accounts payable and accrued liabilities | ($683.0K) | $2.1M | $3.5M | ($6.9M) |
| Net cash provided by operating activities | $184.2M | $98.4M | $261.2M | $161.2M |
| Acquisition of real estate and lease intangibles | ($292.5M) | ($96.1M) | ($301.6M) | ($61.1M) |
| Origination and fundings of loans receivable | ($994.0K) | $0 | ($5.7M) | ($3.1M) |
| Origination and fundings of preferred equity investments | ($669.0K) | ($15.0K) | ($9.0K) | ($9.0K) |
| Additions to real estate | ($25.2M) | ($11.9M) | ($24.2M) | ($13.6M) |
| Escrow deposits for potential investments | ($400.0K) | ($430.0K) | ($500.0K) | — |
| Repayments of loans receivable | $205.1M | $1.9M | $15.4M | $7.0M |
| Repayments of preferred equity investments | $2.3M | $1.3M | $2.0M | $1.4M |
| Investment in unconsolidated joint ventures | $0 | $0 | ($1.2M) | ($1.2M) |
| Net proceeds from the sales of real estate | $93.6M | — | $43.1M | $3.6M |
| Proceeds from net investment hedges | $0 | — | $4.5M | $4.5M |
| Insurance proceeds | $136.0K | $107.0K | $1.3M | $1.0M |
| Net cash used in investing activities | ($18.6M) | ($105.1M) | ($261.4M) | ($61.6M) |
| Net borrowings from revolving credit facility | $100.8M | $137.8M | $174.8M | $55.1M |
| Principal payments on secured debt | ($1.1M) | ($531.0K) | ($1.6M) | ($1.0M) |
| Payments of deferred financing costs | ($92.0K) | ($92.0K) | ($4.4M) | ($80.0K) |
| Contributions from noncontrolling interests | $2.0K | $4.0K | $2.0M | — |
| Distributions to noncontrolling interests | ($119.0K) | — | — | — |
| Payment of contingent consideration | ($1.2M) | ($1.2M) | — | — |
| Issuance of common stock, net | $47.7M | ($8.2M) | $188.3M | $24.2M |
| Dividends paid on common stock | ($151.3M) | ($75.7M) | ($214.7M) | ($142.8M) |
| Net cash used in financing activities | ($5.3M) | $52.1M | $141.7M | ($64.5M) |
| Net increase in cash, cash equivalents and restricted cash | $160.3M | $45.4M | $141.4M | $35.1M |
| Effect of foreign currency translation on cash, cash equivalents and restricted cash | ($132.0K) | ($60.0K) | ($245.0K) | $184.0K |
| Cash, cash equivalents and restricted cash, beginning of period | $78.1M | $78.1M | $66.3M | $66.3M |
| Cash, cash equivalents and restricted cash, end of period | $238.3M | $123.5M | $207.5M | $101.7M |
| Interest paid | $53.8M | $15.1M | $72.8M | $49.7M |
| Decrease in loans receivable and other investments due to acquisition of real estate | $16.6M | — | — | — |
Sabra Healthcare REIT Inc score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.